Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sage Therapeutics, Inc.    SAGE

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/26/2021 03/01/2021 03/02/2021 03/03/2021 03/04/2021 Date
85(c) 87.28(c) 84.14(c) 76.17(c) 70.65(c) Last
1 067 471 404 216 601 323 467 148 846 493 Volume
+1.86% +2.68% -3.60% -9.47% -7.25% Change
More quotes
Financials (USD)
Sales 2021 18,0 M - -
Net income 2021 -444 M - -
Net cash position 2021 1 610 M - -
P/E ratio 2021 -9,08x
Yield 2021 -
Sales 2022 109 M - -
Net income 2022 -373 M - -
Net cash position 2022 1 623 M - -
P/E ratio 2022 -11,2x
Yield 2022 -
Capitalization 4 125 M 4 125 M -
EV / Sales 2021 140x
EV / Sales 2022 23,0x
Nbr of Employees 298
Free-Float 87,5%
More Financials
Company
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's... 
More about the company
Notations Surperformance© of Sage Therapeutics, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about SAGE THERAPEUTICS, INC.
03/02SAGE THERAPEUTICS  : Morgan Stanley Adjusts Sage Therapeutics PT to $87 From $83..
MT
02/26SAGE THERAPEUTICS  : Mizuho Downgrades Sage Therapeutics to Neutral from Buy, Se..
MT
02/25SAGE THERAPEUTICS  : Oppenheimer Adjusts Sage Therapeutics PT to $102 From $90, ..
MT
02/25SAGE THERAPEUTICS  : RBC Adjusts Sage Therapeutics' Price Target to $89 From $86..
MT
02/24SAGE THERAPEUTICS  : Swings to Profit, Posts Higher Revenue in Q4
MT
02/24SAGE THERAPEUTICS  : Management's Discussion and Analysis of Financial Condition..
AQ
02/24SAGE THERAPEUTICS, INC.  : Results of Operations and Financial Condition, Financ..
AQ
02/24SAGE THERAPEUTICS  : Announces Fourth Quarter and Full Year 2020 Financial Resul..
BU
02/24SAGE THERAPEUTICS  : Earnings Flash (SAGE) SAGE THERAPEUTICS Reports Q4 Revenue ..
MT
02/11SAGE THERAPEUTICS  : to Present at Upcoming Investor Conferences
BU
02/10SAGE THERAPEUTICS  : to Report Fourth Quarter and Full Year 2020 Financial Resul..
BU
02/02SAGE THERAPEUTICS  : Raymond James Reinstates Sage Therapeutics at Market Perfor..
MT
01/22SAGE THERAPEUTICS  : BMO Capital Downgrades Sage Therapeutics to Market Perform ..
MT
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
01/19SAGE THERAPEUTICS  : Wedbush Adjusts Price Target on Sage Therapeutics to $98 Fr..
MT
More news
News in other languages on SAGE THERAPEUTICS, INC.
2019Wall Street finit en hausse après une séance hésitante
2019SAGE THERAPEUTICS, INC.  : massacre en vue à Wall Street
2019AVIS D'ANALYSTES DU JOUR  : Air France, BNP Paribas, Teleperformance, DBV Techno..
2019STOCK MARKET PARIS : La Fed choisit la sobriété
2019STOCK MARKET PARIS : Et si l'Allemagne aidait la BCE à relancer la croissance ?
More news
Analyst Recommendations on SAGE THERAPEUTICS, INC.
More recommendations
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 101,20 $
Last Close Price 70,65 $
Spread / Highest target 165%
Spread / Average Target 43,2%
Spread / Lowest Target -0,92%
EPS Revisions
Managers and Directors
NameTitle
Barry E. Greene President, Chief Executive Officer & Director
Kimi E. Iguchi Chief Financial Officer & Treasurer
Kevin Paul Starr Chairman
Albert J. Robichaud Chief Scientific Officer
James Doherty Chief Research Officer
Sector and Competitors
1st jan.Capitalization (M$)
SAGE THERAPEUTICS, INC.-18.33%4 125
MODERNA, INC.25.61%52 458
LONZA GROUP AG-0.63%45 781
CELLTRION, INC.-14.62%36 800
IQVIA HOLDINGS INC.4.14%36 549
SEAGEN INC.-15.54%26 800